DiaMedica Therapeutics Inc. (DMAC) Cash Flow Statement
DiaMedica Therapeutics Inc. (DMAC) generated -$31.5M of operating cash flow over the twelve months to 2026-06-30, spent $33000 on capital expenditure and had free cash flow of -$31.5M, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
DMACDiaMedica Therapeutics Inc.Follow DMAC — free
—
Price chart with a free account
- Market cap
- 470.2M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 18 Nov, in 25 days
| Line | FY2018 Dec 18 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -5.7 | -9.1 | -9.2 | -12.3 | -11.5 | -18.7 | -22.1 | -29.1 | -31.5 | |
| Capital expenditure | 0.1 | 0.0 | 0.0 | 0.0 | 0.1 | 0.0 | 0.0 | 0.0 | -0.0 | |
| Free cash flow | -5.7 | -9.1 | -9.2 | -12.3 | -11.6 | -18.8 | -22.1 | -29.1 | -31.5 | |
| Stock-based compensation | 0.6 | 1.2 | 1.8 | 1.6 | 1.5 | 1.7 | 2.1 | 3.8 | — |
USD millions · SEC XBRL
DiaMedica Therapeutics Inc. — questions
- What is DiaMedica Therapeutics Inc.'s operating cash flow?
- -$31.5M over the twelve months to 2026-06-30.
- How much does DiaMedica Therapeutics Inc. spend on capital expenditure?
- $33000 over the twelve months to 2026-06-30.
- What is DiaMedica Therapeutics Inc.'s free cash flow?
- -$31.5M over the twelve months to 2026-06-30: operating cash flow minus capital expenditure.
Every figure on this page comes from DiaMedica Therapeutics Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.